UroLift® System Research Data from EAU Highlight Durability and Superior Patient Experience, Along with Benefits of Earlier Treatment for BPH
March 13, 2023
Presentations at the 38th Annual European Association of Urology Congress Reinforce Low Surgical Retreatment of the UroLift® System
Read MoreTeleflex Launches National Ad Campaign — “Pit Stop” — to Raise Awareness of the UroLift® System as a Treatment for Enlarged Prostate
February 6, 2023
The campaign drives education about the importance of regular health screenings and treatment options for benign prostatic hyperplasia (BPH), a...
Read MoreTeleflex Celebrates 400,000 Patients Treated With the Minimally Invasive UroLift® System
December 15, 2022
WAYNE, Pa., December 15, 2022 -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that 400,000...
Read MorePublished Data Demonstrate Consistent PUL Outcomes for the Treatment of Median Lobe Obstruction Across Controlled and Real-World Settings
October 25, 2022
Men with obstructive median lobes treated with the UroLift® System experience symptom improvement sooner and are satisfied more quickly compared to...
Read MoreTeleflex Announces Collaboration with FundamentalVR, to Improve Training Through Virtual Reality Simulation
August 25, 2022
FundamentalVR Offers Teleflex a Scalable Training Platform to Accelerate the Effective Use of the UroLift® 2 System for Treatment of Enlarged Prostate
Read MoreTeleflex Announces Pocono Raceway NASCAR Event to Raise Visibility of Enlarged Prostate and the Importance of Regular Health Screenings
July 21, 2022
The company aims to raise awareness and education about BPH, a common men’s health condition
Read MoreNew Data Reinforce Efficacy of the UroLift® System for the Treatment of Enlarged Prostate
July 1, 2022
Presentations at the 37th Annual European Association of Urology Congress to Demonstrate Measurable and Sustained Improvement of BPH Symptoms and...
Read MoreTeleflex Celebrates June Men’s Health Month with Launch of UroLift® Patient Ambassador Program
June 1, 2022
Company Also Announces Milestone of 350,000 UroLift® System Minimally Invasive Procedures Globally
Read MoreTeleflex Announces Regulatory Clearance for its UroLift® System in China for the Treatment of Benign Prostatic Hyperplasia (BPH)
May 19, 2022
Will expand patient access to BPH treatment
Read MoreTeleflex Announces Full U.S. Commercial Launch of the UroLift® 2 System and UroLift ATC® Advanced Tissue Control System
May 13, 2022
Product demonstrations and educational presentations underscore the company’s leadership in advancing care for patients with benign prostatic...
Read More
